Related Experiment Video

Updated: May 27, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Telmisartan for the reduction of cardiovascular morbidity and mortality

Paolo Verdecchia1, Fabio Angeli, Giorgio Gentile

  • 1Unità Operativa Complessa di Medicina, Ospedale di Assisi, Via Valentin Muller, 06081 Assisi, Italy. verdec@tin.it

Expert Review of Clinical Pharmacology
|November 26, 2011
PubMed

Insights

Telmisartan effectively reduces cardiovascular risk, matching ramipril

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) presents a substantial global health and economic challenge.
  • Angiotensin II, a key renin-angiotensin system component, drives atherosclerotic processes contributing to CVD.
  • Renin-angiotensin system blockers lower blood pressure and directly combat atherosclerosis, reducing cardiovascular risk.

Purpose of the Study:

  • To evaluate telmisartan's efficacy in reducing cardiovascular (CV) morbidity and mortality.
  • To compare telmisartan's CV risk reduction profile against ramipril.
  • To highlight telmisartan's unique pharmacological properties and broad clinical indications.

Main Methods:

  • The ONTARGET trial investigated telmisartan versus ramipril in high-CV-risk patients.
  • Pharmacological properties of telmisartan, including plasma half-life, lipophilicity, and receptor binding, were analyzed.
  • Patient populations with existing cardiovascular conditions or diabetes were assessed.

Main Results:

  • Telmisartan demonstrated equivalent efficacy to ramipril in reducing CV morbidity and mortality.
  • Telmisartan exhibited the longest plasma half-life, highest lipophilicity, and strongest receptor binding among angiotensin II receptor blockers (ARBs).
  • Evidence for other ARBs is limited to specific patient subsets, unlike telmisartan's broad applicability.

Conclusions:

  • Telmisartan is a highly effective ARB for reducing cardiovascular risk in a wide patient range.
  • Telmisartan's distinct pharmacological profile supports its broad indication for atherothrombotic disease and diabetes with end-organ damage.
  • Telmisartan offers a valuable therapeutic option for comprehensive cardiovascular risk management.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...